Literature DB >> 1623911

The pharmacokinetics of nifurtimox in chronic renal failure.

G González-Martin1, S Thambo, C Paulos, I Vásquez, J Paredes.   

Abstract

The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1623911     DOI： 10.1007/bf00265935

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western Hemisphere.

Authors:  Z Brener
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

2.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

3.  High-performance liquid chromatographic determination of nifurtimox in human serum.

Authors:  C Paulos; J Paredes; I Vasquez; G Kunze; G González-Martin
Journal:  J Chromatogr       Date:  1988-12-09

4.  [Biological and ecological factors in the epidemiology of Chagas' disease in Chile (author's transl)].

Authors:  H Schenone; F Villarroel; A Rojas; E Alfaro
Journal:  Bol Chil Parasitol       Date:  1980 Jul-Dec

5.  Studies with Bay 2502 on animals.

Authors:  M Bock; R Gönnert; A Haberkorn
Journal:  Bol Chil Parasitol       Date:  1969 Jan-Mar

6.  Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers.

Authors:  C Paulos; J Paredes; I Vasquez; S Thambo; A Arancibia; G Gonzalez-Martin
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-09

7.  [Chagas' disease in patients with renal transplantation].

Authors:  S Thambo; W Passalacqua; R Van Cauwelaert; F Lazcano
Journal:  Rev Med Chil       Date:  1989-01       Impact factor: 0.553

Review 8.  Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi.

Authors:  R Docampo; S N Moreno
Journal:  Rev Infect Dis       Date:  1984 Mar-Apr

9.  Nitroreduction of benznidazole and nifurtimox by rat and human feces.

Authors:  E G de Toranzo; M Masana; J A Castro
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-08

10.  Studies on nifurtimox nitroreductase activity in liver and other rat tissues.

Authors:  M Masana; E G de Toranzo; J A Castro
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-07
View more
  10 in total

1.  The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriers.

Authors:  Sinthujah Jeganathan; Lisa Sanderson; Murat Dogruel; Jean Rodgers; Simon Croft; Sarah A Thomas
Journal:  J Pharmacol Exp Ther       Date:  2010-11-05       Impact factor: 4.030

2.  Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Authors:  Maribel Reyes; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2011-05-26       Impact factor: 3.534

3.  Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.

Authors:  Lisa Sanderson; Adil Khan; Sarah Thomas
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

4.  Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Harry Pieter De Koning; Sarah Ann Thomas
Journal:  J Pharmacol Exp Ther       Date:  2009-03-04       Impact factor: 4.030

Review 5.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 6.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

7.  The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Barbara Bradley; Sarah Ann Thomas
Journal:  J Neurochem       Date:  2008-09-24       Impact factor: 5.372

8.  Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.

Authors:  Michael Du; Linna Zhang; Kathleen A Scorsone; Sarah E Woodfield; Peter E Zage
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

Review 9.  Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria.

Authors:  María Álvarez-Bardón; Yolanda Pérez-Pertejo; César Ordóñez; Daniel Sepúlveda-Crespo; Nestor M Carballeira; Babu L Tekwani; Sankaranarayanan Murugesan; Maria Martinez-Valladares; Carlos García-Estrada; Rosa M Reguera; Rafael Balaña-Fouce
Journal:  Mar Drugs       Date:  2020-03-31       Impact factor: 5.118

10.  Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease.

Authors:  Heino Stass; Ethel Feleder; Facundo Garcia-Bournissen; Johannes Nagelschmitz; Boris Weimann; Gustavo Yerino; Jaime Altcheh
Journal:  Clin Pharmacol Drug Dev       Date:  2020-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.